Form PTO 1449 (Modified)				ATTY DOCKET NO. 217408US0CONT	SERIAL NO. NEW APPLICATION			
LIST OF	REFER	RENCES CITED BY APPL	ICANT	APPLICANT Chika NAKANISHI et al.				
	,			FILING DATE HEREWITH		GROUP	28.	
				U.S. PATENT DOCUMENTS			20°	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB. CLASS	FILING CATE	
100-	AA	5,767,129	06-16-98	Yuen				
<i>Y</i> .	AB.							
	AC	· / K1/K	. ,					
	AD	Mon		5/10/07			· .	
	AE							
	AF				, -			
	AG		,			·		
·	AH							
	AI		•					
	AJ							
	AK			•		·		
	AL							
	AM							
	AN							
			FO	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER				TRANSLATION YES NO		
96	AO	EP 0 705 819	04-10-96	Europe				
-92	AP	WO 98/49144	-11-05-98	Japan w/English Abstract Attached			/	
9	AQ ·	WO 60233058 JPX	11-19-85	Japan w/English Abstract Attached	•			
4.0	AR	WO 93/13128	07-08-93					
de	AS	WO 00/24716	05-04-00	Japan w/English Abstract Attached				
3.0	AT	WO 99/32446	07-01-99	Japan w/English Abstract Attached				
	AU		·					
·	AV							
		OTHER REF	ERENCES (ncluding Author, Title, Date, Pertine	nt Pages, e	tc.)		
9.6	Virginia D. Monje et al., <u>A New Conus Peptide Ligand for Ca Channel Subtypes</u> , Neuropharmacology, Vol. 32, No. 11, pages 1141-1149, 1993.							
9.3	AX	Hisayuki Uneyama et al., <u>Blockage of N-type Ca²⁺ Current by Citnidipine (FRC-8653) in Acutely Dissociated Rat Symbathetic Neurones</u> , <u>British Journal of Pharmacology</u> Volume 122, pages 37-42, 1997.						
9.7	AY	Shigeo Fujii et al., Effect of Clinidigine, a Novel Dihydropyridine Ca++ -channel Antagonist, on N-type Ca++ Channel in Rat Darsal Root Ganglion Neurons, The Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 3, pages 1184-1191, 1997.						
	AZ					•		
Examiner	Date Considered 16/03							
Examiner: Iniconformance	tial if n	eference is considered, what considered, Include con-	nether or not	citation is in conformance with MPEP with next communication to applicant.	609; Draw li	ne through	citation if not in	

20%